A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Summary

The project was undertaking by Qilu Hospital, Shandong University and other several well-known hospitals in China. In order to report the efficacy and safety of Rituximab in different frequencies for the treatment of adults with steroid-resistant/relapsed immune thrombocytopenia (ITP).

Timeline

Start

2014-05

Primary completion

2015-01

Completion

2016-01

Outcome

Outcome not reported

Stopped (Enrollment): “No eligible patient was enrolled.”

Drugs

Indications